The IPO Buzz: Contineum Therapeutics Prices Downsized IPO at $16.00 – Low End – & Stock Falls in Debut
Contineum Therapeutics (CTNM), a Phase 1/Phase 2 biotech, priced its downsized IPO at $16.00 – the low end of its $16.00-to-$18.00 range – on Thursday night, April 4, 2024. The deal’s size was slashed to 6.88 million shares (6,875,000 shares) – down from 8.8 million shares in the prospectus. Contineum Therapeutics raised $110.0 million – well below […]
April 4, 2024 Read More